Cytonics
[Closed for Investment] Cytonics Corporation, with a pre-money valuation of $46.7 million, is raising funds on SeedInvest through Reg A+ crowdfunding. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. Cytonics Corporation was founded by Gaetano Scuderi and has raised over $15 million in previous rounds of financing. The current round of funding has a minimum raise of $1,500,000 and a maximum raise of $19,000,000, and the funds will be used for GMP production of CYT-108, GLP pre-clinical animal study, Phase 1 human clinical trial, and Phase 2 human clinical trial. Cytonics Corporation has already initiated a pilot pre-clinical study for its lead drug candidate CYT-108 in 2019. It is a biologic therapy modeled after the naturally occurring A2M molecule found in the blood.
Investment Overview
Raised: $4,667,638
Deal Terms
Company & Team
Company
- Year Founded
- 2006
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
08/25/2024 | StartEngine | $66,557,294 | $938,436 | Equity - Preferred | Funded | RegCF |
05/28/2024 | StartEngine | $65,792,080 | $3,626,034 | Equity - Preferred | Funded | RegCF |
03/31/2023 | Dealmaker Securities | $58,915,995 | $1,695,868 | Equity - Preferred | Funded | RegCF |
10/14/2022 | SeedInvest | $58,915,996 | $2,633,766 | Equity - Preferred | Funded | RegCF / RegD 506(c) |
04/30/2021 | SeedInvest | $46,701,000 | $4,667,638 | Equity - Preferred | Funded | RegA+ |
05/18/2019 | SeedInvest | $32,400,000 | $494,344 | Convertible Note | Funded | RegCF / RegD 506(c) |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.